Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.67 |
| ▸ | DPP4 | P27487 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.67 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.67 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.67 |
| ▸ | GAPDH | P04406 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | STAT6 | P42226 | 1/20 | 0.67 |
| ▸ | PI4KA | P42356 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.67 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.67 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120562 | 0.99 | ADORA3 (0.68) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL10689183 | 0.96 | ADORA3 (0.73) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL8608782 | 0.93 | ADORA3 (0.69) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL8609365 | 0.93 | ADORA3 (0.69) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL8608418 | 0.91 | ADORA1 (0.61) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL5063589 | 0.90 | ADORA1 (0.65) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL7909170 | 0.89 | MEN1 (0.57) | ADORA3ADORA1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8606939 | 0.89 | ADORA1 (0.64) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL8606410 | 0.89 | ADORA1 (0.64) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL3699111 | 0.88 | MEN1 (0.59) | ADORA3ADORA1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 845 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| US-20190125779-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2019-05-02 | — | — | US | claimed |
| WO-2018091689-A1 | SKELETAL MUSCLE HYPERTROPHY INDUCERS | CYTOO (FR) | 2018-05-24 | — | — | WO | claimed |
| EP-3247715-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | Inotek Pharmaceuticals Corporation (US) | 2017-11-29 | — | — | EP | claimed |
| WO-2017137528-A1 | ADENOSINE A1 RECEPTOR AGONIST FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2017-08-17 | — | — | WO | claimed |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION | 2016-12-22 | — | — | US | claimed |
| WO-2016109624-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2016-07-07 | — | — | WO | claimed |
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | claimed |
| US-20160158267-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | claimed |
| WO-2016090005-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-06-09 | — | — | WO | claimed |
| WO-1998019674-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | HEAD EXPLORER APS (DK) | 1998-05-14 | — | — | WO | claimed |
| WO-1998015276-A1 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | THERASYS, INC. (US) | 1998-04-16 | — | — | WO | claimed |
| EP-0735888-A1 | PURINE COMPOSITIONS AND METHODS FOR ADMINISTRATION | FUKUNAGA, Atsuo F. (US) | 1996-10-09 | — | — | EP | claimed |
| WO-1995014478-A1 | PURINE COMPOSITIONS AND METHODS FOR ADMINISTRATION | FUKUNAGA ATSUO F (US) | 1995-06-01 | — | — | WO | claimed |
| EP-0589964-A4 | METHOD AND COMPOSITION TO REDUCE MYOCARDIAL REPERFUSION INJURY | UNIV VANDERBILT (US) | 1994-05-25 | — | — | EP | claimed |
| EP-0589964-A1 | METHOD AND COMPOSITION TO REDUCE MYOCARDIAL REPERFUSION INJURY | VANDERBILT UNIVERSITY (US) | 1994-04-06 | — | — | EP | claimed |
| WO-1992020346-A1 | METHOD AND COMPOSITION TO REDUCE MYOCARDIAL REPERFUSION INJURY | VANDERBILT UNIVERSITY (US) | 1992-11-26 | — | — | WO | claimed |
| US-5070877-A | Using adenosin receptor agonist | MEDCO RESEARCH, INC. (US) | 1991-12-10 | — | — | US | claimed |
| EP-0181129-B1 | N6-SUBSTITUTED DEOXYRIBOSE ANALOGS OF ADENOSINES | WARNER-LAMBERT COMPANY (US) | 1989-03-08 | — | — | EP | claimed |
| EP-0181129-A2 | N6-substituted deoxyribose analogs of adenosines | WARNER-LAMBERT COMPANY (US) | 1986-05-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158267-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | ADORA2A, ADORA1, PDE6C | ADORA3 4/4885ADORA1 2/4885SMN1; SMN2 1976/4885 |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | PTGIR, ADORA1, PDE3A | ADORA3 7/4885ADORA1 2/4885SMN1; SMN2 4752/4885 |
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA3 31/4885ADORA1 18/4885SMN1; SMN2 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.